Acorda Therapeutics

Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda has an industry leading pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and multiple sclerosis. 
The ARCUS technology platform allows for delivery of medication through inhalation. It has been used in clinical trials across a broad spectrum of applications: local and systemic disease targets, large and small molecules, and a wide range of doses. The Company has two clinical-stage programs that use the ARCUS technology: CVT-301 (symptoms of OFF periods in Parkinson’s disease) and CVT-427 (acute treatment of migraine).

Company Growth (employees)
Type
Public
HQ
Ardsley, US
Founded
1995
Size (employees)
597 (est)
Website
acorda.com
Acorda Therapeutics was founded in 1995 and is headquartered in Ardsley, US

Acorda Therapeutics Office Locations

Acorda Therapeutics has offices in Ardsley, Chelsea, South San Francisco and Waltham
Ardsley, US (HQ)
420 Saw Mill River Rd
Waltham, US
283 Bear Hill Rd
South San Francisco, US
701 Gateway Blvd
Chelsea, US
190 Everett Ave

Acorda Therapeutics Data and Metrics

Acorda Therapeutics Financial Metrics

Acorda Therapeutics's revenue was reported to be $119.4 m in Q1, 2017
USD

Revenue (Q1, 2017)

119.4 m

Gross profit (Q1, 2017)

94.2 m

Gross profit margin (Q1, 2017), %

79%

Net income (Q1, 2017)

(18.9 m)

EBIT (Q1, 2017)

(15.3 m)

Market capitalization (15-Aug-2017)

974 m

Cash (31-Mar-2017)

133.6 m
Acorda Therapeutics's current market capitalization is $974 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

336.4 m401.5 m492.7 m519.6 m

Revenue growth, %

19%23%5%

Cost of goods sold

66 m80 m92.3 m107.5 m

Gross profit

270.4 m321.5 m400.4 m412.1 m

Gross profit Margin, %

80%80%81%79%

R&D expense

53.9 m73.5 m149.2 m203.4 m

General and administrative expense

185.5 m201.8 m205.6 m235.4 m

Operating expense total

306.1 m365.1 m458.7 m555.6 m

EBIT

30.4 m36.4 m34 m(36 m)

EBIT margin, %

9%9%7%(7%)

Interest expense

(2.2 m)(9.3 m)(15.5 m)(16.5 m)

Interest income

668 k674 k440 k339 k

Pre tax profit

28.9 m28 m19.4 m(42.3 m)

Income tax expense

(8.3 m)6.7 m

Net Income

16.4 m17.7 m11.1 m(35.6 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

97.1 m106 m99.9 m113.7 m148.2 m115.9 m127.5 m135.6 m119.4 m

Cost of goods sold

18.9 m20.6 m18.4 m22.7 m24.7 m23.2 m26.4 m27.6 m25.2 m

Gross profit

78.2 m85.4 m81.4 m91 m123.5 m92.7 m101 m108 m94.2 m

Gross profit Margin, %

81%81%82%80%83%80%79%80%79%

R&D expense

16.4 m16.6 m30.6 m31.2 m43.4 m44.6 m50.3 m54.8 m46.5 m

General and administrative expense

50.6 m47.8 m48.8 m52.8 m51.1 m59 m62.6 m54.8 m52 m

Operating expense total

67.1 m64.4 m79.4 m84 m94.4 m103.6 m112.9 m109.6 m98.5 m

EBIT

11 m20.8 m(1.3 m)5.7 m25.7 m(17.2 m)(14 m)(5.5 m)(15.3 m)

EBIT margin, %

11%20%(1%)5%17%(15%)(11%)(4%)(13%)

Interest expense

(426 k)(4.6 m)(4.1 m)(4 m)(4 m)(3.7 m)(4 m)(4.4 m)(4.1 m)

Interest income

165 k257 k66 k94 k120 k215 k48 k46 k38 k

Pre tax profit

10.7 m16.5 m(5.1 m)21.7 m(19.9 m)(10 m)

Income tax expense

(6 m)(4.5 m)(17.8 m)972 k

Net Income

5.4 m17.3 m(3.1 m)(2.1 m)1.9 m(520 k)(19.5 m)(32.5 m)(18.9 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

48 m182.2 m153.2 m158.5 m

Accounts Receivable

1 m71.3 m

Inventories

43.1 m

Current Assets

367.3 m409.1 m451.3 m272.7 m

PP&E

16.5 m46.1 m40.2 m34.3 m

Goodwill

183 m183.6 m280.6 m

Total Assets

607.1 m1.1 b1.1 b1.3 b

Accounts Payable

15.9 m17.8 m14.2 m26.9 m

Total Debt

331.1 m

Current Liabilities

96.6 m114.4 m90.6 m147.9 m

Common Stock

46 k

Additional Paid-in Capital

678.7 m761 m812.8 m921.4 m

Retained Earnings

(238.1 m)(220.4 m)(209.4 m)(244 m)

Total Equity

440.4 m540.3 m603 m664.2 m

Debt to Equity Ratio

0.5 x

Debt to Assets Ratio

0.2 x

Financial Leverage

1.4 x2 x1.9 x2 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

274.6 m53.3 m61.5 m76.2 m89.8 m431.4 m137.4 m127.9 m133.6 m

Inventories

30.8 m26.6 m45.3 m48.6 m46.8 m

Current Assets

693.1 m843.9 m423.8 m427.6 m429.6 m544.3 m263.2 m238 m248.2 m

PP&E

15.8 m17.1 m45.9 m44.5 m42.4 m38 m36.8 m35.8 m37.1 m

Goodwill

183 m183 m183.6 m183.6 m284.5 m284 m278.1 m

Total Assets

943.3 m972.8 m1.1 b1.1 b1.1 b1.2 b1.3 b1.3 b1.3 b

Accounts Payable

20.7 m20.5 m21.9 m16.9 m14 m21.4 m29.6 m18.6 m21.4 m

Current Liabilities

94.6 m100.9 m122.2 m111.7 m93.2 m105 m136.1 m118.1 m119.3 m

Additional Paid-in Capital

733.3 m743.8 m772.9 m783.1 m793.8 m894.2 m904.8 m911.5 m937.7 m

Retained Earnings

(232.7 m)(220.7 m)(223.5 m)(222.5 m)(218.6 m)(209.9 m)(228.2 m)(240.9 m)(250.8 m)

Total Equity

500.4 m522.9 m549 m560.3 m574.9 m684 m681.5 m666.8 m676.1 m

Financial Leverage

1.9 x1.9 x2 x2 x1.9 x1.8 x2 x2 x2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

16.4 m17.7 m11.1 m(35.6 m)

Depreciation and Amortization

7 m8.5 m15 m21.6 m

Accounts Receivable

(4.5 m)(1.4 m)744 k(20 m)

Inventories

(10.2 m)(6.7 m)

Accounts Payable

59.9 k59.9 k37.6 m

Cash From Operating Activities

6.2 m134.1 m(29 m)35.3 m

Purchases of PP&E

(4 m)(5.1 m)(5.9 m)(6.2 m)

Cash From Investing Activities

(45.1 m)(293.8 m)(85.2 m)(73.8 m)

Cash From Financing Activities

12 m352.9 m17.8 m45.9 m

Interest Paid

2 m4.5 m7.2 m6.1 m

Income Taxes Paid

2.6 m4.4 m4.7 m4.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

5.4 m17.3 m(3.1 m)(2.1 m)1.9 m(520 k)(19.5 m)(32.5 m)(18.9 m)

Depreciation and Amortization

3.6 m5.4 m3.7 m7.5 m11.2 m3.9 m9.9 m15.8 m5.6 m

Accounts Receivable

3.8 m6 m1.7 m2.4 m455 k(10.2 m)(14.3 m)(17 m)2 m

Inventories

(5.3 m)(1.1 m)(19 m)(22.4 m)(20.6 m)

Cash From Operating Activities

23 m61.4 m(9.3 m)(6 m)16.2 m6.7 m(2.9 m)2.9 m(25.4 m)

Purchases of PP&E

(1.4 m)(2.3 m)(2.6 m)(4.1 m)(5 m)(1 m)(2.5 m)(4.6 m)(5.8 m)

Cash From Investing Activities

(138 m)(400.8 m)(116 m)(106.1 m)(116.3 m)198.3 m(71.2 m)(73.5 m)(5.8 m)

Cash From Financing Activities

341.6 m344.7 m4.6 m6.1 m7.8 m73.2 m58 m45.1 m6 m

Interest Paid

706 k1.2 m463 k4 m4.3 m21 k3 m3 m29 k

Income Taxes Paid

1.2 m1.8 m743 k1.3 m2.2 m157 k2.6 m3.6 m1.9 m
USDY, 2017

Revenue/Employee

200 k

Financial Leverage

2 x

Acorda Therapeutics Market Value History

Acorda Therapeutics Job Categories

Traffic Overview of Acorda Therapeutics

Acorda Therapeutics Online and Social Media Presence

Acorda Therapeutics Company Life and Culture

You may also be interested in